Table 1.

Key Questions.

1	When should CAPA/IAPA be suspected?
2	What diagnostic methods should be used to establish CAPA/IAPA diagnosis and when should they be applied?
3	What to do when it is impossible to use certain diagnostic methods? What approach should be taken when certain diagnostic methods are not possible?
4	What is the recommended antifungal treatment in CAPA/IAPA?
5	Which antifungal treatment is the most suitable if resistance-related problems arise? When should we suspect resistance in CAPA/IAPA?
6	In what situations should we monitor whether treatment is appropriate or Not?
7	How should treatment failure be defined and what procedure should be followed if this occurs?
8	In CAPA/IAPA patients, is the administration of corticosteroids associated with increased mortality and/or increased incidence of pneumonia associated with mechanical ventilation?
9	In CAPA/IAPA patients, is combined antifungal therapy associated with lower mortality and/or a shorter hospital stay? In which CAPA/IAPA patients is combined antifungal therapy associated with lower mortality and/or shorter hospital stay?
10	When should antifungal treatment be withdrawn in CAPA/IAPA patients?
11	What is the management approach for patients with viral pneumonia caused by influenza/COVID-19 with a positive culture for Aspergillus?
12	In what type of patients could antifungal prophylaxis be recommended? In what type of patients with severe viral pneumonia could antifungal prophylaxis be recommended?